Insights into the Mechanism of Osteoporosis and the Available Treatment Options


Cite item

Full Text

Abstract

Osteoporosis, one of the most prevalent bone illnesses, majorly affects postmenopausal women and men over 50 years of age. Osteoporosis is associated with an increased susceptibility to fragility fractures and can result in persistent pain and significant impairment in affected individuals. The primary method for diagnosing osteoporosis involves the assessment of bone mineral density (BMD) through the utilisation of dual energy x-ray absorptiometry (DEXA). The integration of a fracture risk assessment algorithm with bone mineral density (BMD) has led to significant progress in the diagnosis of osteoporosis. Given that osteoporosis is a chronic condition and multiple factors play an important role in maintaining bone mass, comprehending its underlying mechanism is crucial for developing more effective pharmaceutical interventions for the disease. The effective management of osteoporosis involves the utilisation of appropriate pharmacological agents in conjunction with suitable dietary interventions and lifestyle modifications. This review provides a comprehensive understanding of the types of osteoporosis and elucidates the currently available pharmacological treatment options and their related mechanism of action and usage.

About the authors

Rajeshwari Muniyasamy

School of BioSciences and Technology, Vellore Institute of Technology

Email: info@benthamscience.net

Inderchand Manjubala

School of BioSciences and Technology, Vellore Institute of Technology

Author for correspondence.
Email: info@benthamscience.net

References

  1. Klibanski, A.; Adams-Campbell, L.; Bassford, T.; Blair, S.N.; Boden, S.D.; Dickersin, K. Osteoporosis prevention, diagnosis, and therapy. JAMA, 2001, 285(6), 785-795. doi: 10.1001/jama.285.6.785 PMID: 11176917
  2. Sözen, T. Özışık, L.; Calik Basaran, N. An overview and management of osteoporosis. Eur. J. Rheumatol., 2017, 4(1), 46-56. doi: 10.5152/eurjrheum.2016.048 PMID: 28293453
  3. Mahakala, A.; Thoutreddy, S.; Kleerekoper, M. Prevention and treatment of postmenopausal osteoporosis. Treat. Endocrinol., 2003, 2(5), 331-345. doi: 10.2165/00024677-200302050-00005 PMID: 15981950
  4. Johnell, O.; Kanis, J. Epidemiology of osteoporotic fractures. Osteoporos. Int., 2005, 16(S02), S3-S7. doi: 10.1007/s00198-004-1702-6 PMID: 15365697
  5. Akkawi, I.; Zmerly, H. Osteoporosis: Current concepts. Joints, 2018, 6(2), 122-127. doi: 10.1055/s-0038-1660790 PMID: 30051110
  6. Johnell, O.; Kanis, J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int., 2006, 17(12), 1726-1733. doi: 10.1007/s00198-006-0172-4 PMID: 16983459
  7. Key statistic for Asia. International osteoporosis foundation. 2006. Available from: https://www.osteoporosis.foundation/factsstatistics/key-statistic-for-asia.
  8. Pouresmaeili, F.; Kamali Dehghan, B.; Kamarehei, M.; Yong Meng, G. A comprehensive overview on osteoporosis and its risk factors. Ther. Clin. Risk Manag., 2018, 14, 2029-2049. doi: 10.2147/TCRM.S138000 PMID: 30464484
  9. Pinkerton, J.; Thomas, S.; Dalkin, A.C. Osteoporosis treatment and prevention for postmenopausal women: Current and future therapeutic options. Clin. Obstet. Gynecol., 2013, 56(4), 711-721. doi: 10.1097/GRF.0b013e3182a9fb02 PMID: 24100598
  10. Barnsley, J.; Buckland, G.; Chan, P.E.; Ong, A.; Ramos, A.S.; Baxter, M.; Laskou, F.; Dennison, E.M.; Cooper, C.; Patel, H.P. Pathophysiology and treatment of osteoporosis: Challenges for clinical practice in older people. Aging Clin. Exp. Res., 2021, 33(4), 759-773. doi: 10.1007/s40520-021-01817-y PMID: 33742387
  11. Seeman, E.; Martin, T.J. Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat. Rev. Rheumatol., 2019, 15(4), 225-236. doi: 10.1038/s41584-019-0172-3 PMID: 30755735
  12. Pavone, V.; Testa, G.; Giardina, S.M.C.; Vescio, A.; Restivo, D.A.; Sessa, G. Pharmacological therapy of osteoporosis: A systematic current review of literature. Front. Pharmacol., 2017, 8, 803. doi: 10.3389/fphar.2017.00803 PMID: 29163183
  13. Del Valle, H.; Yaktine, A.; Taylor, C.; Ross, A. Dietary reference intakes for calcium and vitamin D; National Academies Press: US, 2011. doi: 10.17226/13050
  14. Sinaki, M.; Pfeifer, M. Non-Pharmacological Management of Osteoporosis: Exercise, Nutrition, Fall and Fracture Prevention, 1st ed; Springer Cham, 2017. doi: 10.1007/978-3-319-54016-0
  15. Bauman, A.; Merom, D.; Bull, F.C.; Buchner, D.M.; Fiatarone Singh, M.A. Updating the evidence for physical activity: Summative reviews of the epidemiological evidence, prevalence, and interventions to promote "Active Aging". Gerontologist, 2016, 56(Suppl. 2), S268-S280. doi: 10.1093/geront/gnw031 PMID: 26994266
  16. Fares, A. Pharmacological and non-pharmacological means for prevention of fractures among elderly. Int. J. Prev. Med., 2018, 9(1), 78. doi: 10.4103/ijpvm.IJPVM_114_18 PMID: 30283610
  17. Ansari, N.; Sims, N.A. The cells of bone and their interactions. Handb. Exp. Pharmacol., 2019, 262, 1-25. doi: 10.1007/164_2019_343 PMID: 32006260
  18. Franz-Odendaal, T.A.; Hall, B.K.; Witten, P.E. Buried alive: How osteoblasts become osteocytes. Dev. Dyn., 2006, 235(1), 176-190. doi: 10.1002/dvdy.20603 PMID: 16258960
  19. Rochefort, G.Y.; Pallu, S.; Benhamou, C.L. Osteocyte: The unrecognized side of bone tissue. Osteoporos. Int., 2010, 21(9), 1457-1469. doi: 10.1007/s00198-010-1194-5 PMID: 20204595
  20. Florencio-Silva, R.; Sasso, G.R.S.; Sasso-Cerri, E.; Simões, M.J.; Cerri, P.S. Biology of bone tissue: Structure, function, and factors that influence bone cells. BioMed Res. Int., 2015, 2015, 1-17. doi: 10.1155/2015/421746 PMID: 26247020
  21. Mohamed, A.M.F.S. An overview of bone cells and their regulating factors of differentiation. Malays. J. Med. Sci., 2008, 15(1), 4-12. PMID: 22589609
  22. Boyle, W.J.; Simonet, W.S.; Lacey, D.L. Osteoclast differentiation and activation. Nature, 2003, 423(6937), 337-342. doi: 10.1038/nature01658 PMID: 12748652
  23. Henriksen, K.; Bollerslev, J.; Everts, V.; Karsdal, M.A. Osteoclast activity and subtypes as a function of physiology and pathology--implications for future treatments of osteoporosis. Endocr. Rev., 2011, 32(1), 31-63. doi: 10.1210/er.2010-0006 PMID: 20851921
  24. Tella, S.H.; Gallagher, J.C. Prevention and treatment of postmenopausal osteoporosis. J. Steroid Biochem. Mol. Biol., 2014, 142, 155-170. doi: 10.1016/j.jsbmb.2013.09.008 PMID: 24176761
  25. Sebastian, A. Loots, GG Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models. Metab - Clin. Exp., 2018, 80, 38-47. doi: 10.1016/j.metabol.2017.10.005
  26. Della Corte, A.; Giorgio, I.; Scerrato, D. A review of recent developments in mathematical modeling of bone remodeling. Proc. Inst. Mech. Eng. H, 2020, 234(3), 273-281. doi: 10.1177/0954411919857599 PMID: 31203749
  27. Allen, M.R.; Burr, D.B. Bone Modeling and Remodeling. In: Basic and Applied Bone Biology; Elsevier, 2013; pp. 75-90. doi: 10.1016/B978-0-12-416015-6.00004-6
  28. Langdahl, B.; Ferrari, S.; Dempster, D.W. Bone modeling and remodeling: Potential as therapeutic targets for the treatment of osteoporosis. Ther. Adv. Musculoskelet. Dis., 2016, 8(6), 225-235. doi: 10.1177/1759720X16670154 PMID: 28255336
  29. Feng, X.; McDonald, J.M. Disorders of bone remodeling. Annu. Rev. Pathol., 2011, 6(1), 121-145. doi: 10.1146/annurev-pathol-011110-130203 PMID: 20936937
  30. Ji, M.X.; Yu, Q. Primary osteoporosis in postmenopausal women. Chronic Dis. Transl. Med., 2015, 1(1), 9-13. doi: 10.1016/j.cdtm.2015.02.006 PMID: 29062981
  31. Novais, A.; Chatzopoulou, E.; Chaussain, C.; Gorin, C. The potential of FGF-2 in craniofacial bone tissue engineering: A review. Cells, 2021, 10, 932. doi: 10.3390/cells10040932
  32. Kontulainen, S.; Sievänen, H.; Kannus, P.; Pasanen, M.; Vuori, I. Effect of long-term impact-loading on mass, size, and estimated strength of humerus and radius of female racquet-sports players: A peripheral quantitative computed tomography study between young and old starters and controls. J. Bone Miner. Res., 2002, 17(12), 2281-2289. doi: 10.1359/jbmr.2002.17.12.2281 PMID: 12469923
  33. Sugiyama, T.; Oda, H. Osteoporosis therapy: Bone modeling during growth and aging. Front. Endocrinol., 2017, 8, 46. doi: 10.3389/fendo.2017.00046 PMID: 28337176
  34. Ozel, S.; Switzer, L.; Macintosh, A.; Fehlings, D. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: An update. Dev. Med. Child Neurol., 2016, 58(9), 918-923. doi: 10.1111/dmcn.13196 PMID: 27435427
  35. Hattner, R.; Epker, B.N.; Frost, H.M. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature, 1965, 206(4983), 489-490. doi: 10.1038/206489a0 PMID: 5319106
  36. Mora, S.; Gilsanz, V. Establishment of peak bone mass. Endocrinol. Metab. Clin. North Am., 2003, 32(1), 39-63. doi: 10.1016/S0889-8529(02)00058-0 PMID: 12699292
  37. Coughlan, T.; Dockery, F. Osteoporosis and fracture risk in older people. Clin. Med., 2014, 14(2), 187-191. doi: 10.7861/clinmedicine.14-2-187 PMID: 24715132
  38. Tuck, S.P.; Francis, R.M. Osteoporosis. Postgrad. Med. J., 2002, 78(923), 526-532. doi: 10.1136/pmj.78.923.526 PMID: 12357012
  39. Sheu, A.; Diamond, T. Diagnostic Tests: Bone mineral density: Testing for osteoporosis. Aust. Prescr., 2016, 39(2), 35-39. doi: 10.18773/austprescr.2016.020 PMID: 27340320
  40. World Health Organization. FRAXA WHO Fracture Risk Assessment Tool., Available from: http://www.shef.ac.uk/FRAX/
  41. Compston, J.; Cooper, A.; Cooper, C.; Gittoes, N.; Gregson, C.; Harvey, N.; Hope, S.; Kanis, J.A.; McCloskey, E.V.; Poole, K.E.S.; Reid, D.M.; Selby, P.; Thompson, F.; Thurston, A.; Vine, N. UK clinical guideline for the prevention and treatment of osteoporosis. Arch. Osteoporos., 2017, 12(1), 43. doi: 10.1007/s11657-017-0324-5 PMID: 28425085
  42. Mirza, F.; Canalis, E. Management of endocrine disease: Secondary osteoporosis: Pathophysiology and management. Eur. J. Endocrinol., 2015, 173(3), R131-R151. doi: 10.1530/EJE-15-0118 PMID: 25971649
  43. Pacifici, R. Mechanisms of estrogen action in bone. Princ Bone Biol Two-Volume Set, 2008, 1, 921-933. doi: 10.1016/B978-0-12-373884-4.00059-8
  44. Khosla, S.; Oursler, M.J.; Monroe, D.G. Estrogen and the skeleton. Trends Endocrinol. Metab., 2012, 23(11), 576-581. doi: 10.1016/j.tem.2012.03.008 PMID: 22595550
  45. Zhang, D-M; Cui, D-X; Xu, R-S; Zhou, Y-C; Zheng, L-W Liu, P Phenotypic research on senile osteoporosis caused by SIRT6 deficiency. Int. J. Oral Sci., 2016, 8, 84-92. doi: 10.1038/ijos.2015.57
  46. Qadir, A; Liang, S; Wu, Z; Chen, Z; Hu, L; Qian, A Senile osteoporosis: The involvement of differentiation and senescence of bone marrow stromal cells. Int. J. Mol. Sci., 2020, 21(1), 349. doi: 10.3390/ijms21010349
  47. Johnston, C.B.; Dagar, M. Osteoporosis in older adults. Med. Clin. North Am., 2020, 104(5), 873-884. doi: 10.1016/j.mcna.2020.06.004 PMID: 32773051
  48. Santos, L.; Elliott-Sale, K.J.; Sale, C. Exercise and bone health across the lifespan. Biogerontology, 2017, 18, 931-946. doi: 10.1007/s10522-017-9732-6
  49. Lane, N.E. Epidemiology, etiology, and diagnosis of osteoporosis. Am. J. Obstet. Gynecol., 2006, 194(2), S3-S11. doi: 10.1016/j.ajog.2005.08.047 PMID: 16448873
  50. Minisola, S.; Cipriani, C.; Occhiuto, M.; Pepe, J. New anabolic therapies for osteoporosis. Intern. Emerg. Med., 2017, 12(7), 915-921. doi: 10.1007/s11739-017-1719-4 PMID: 28780668
  51. Palacios, S. Medical treatment of osteoporosis. Climacteric, 2022, 25(1), 43-49. doi: 10.1080/13697137.2021.1951697 PMID: 34382489
  52. Haas, A.V.; LeBoff, M.S. Osteoanabolic agents for osteoporosis. J. Endocr. Soc., 2018, 2(8), 922-932. doi: 10.1210/js.2018-00118 PMID: 30087947
  53. Mihaylova, L.; Peikova, L.; Obreshkova, D. Osteoporosis: Therapeutic options. Folia Med., 2015, 57(3-4), 181-190. doi: 10.1515/folmed-2015-0037
  54. Banu, J.; Varela, E.; Fernandes, G. Alternative therapies for the prevention and treatment of osteoporosis. Nutr. Rev., 2012, 70(1), 22-40. doi: 10.1111/j.1753-4887.2011.00451.x PMID: 22221214
  55. Chen, L.R.; Ko, N.Y.; Chen, K.H. Medical treatment for osteoporosis: From molecular to clinical opinions. Int. J. Mol. Sci., 2019, 20(9), 2213. doi: 10.3390/ijms20092213 PMID: 31064048
  56. Camacho, P.M.; Petak, S.M.; Binkley, N.; Clarke, B.L.; Harris, S.T.; Hurley, D.L.; Kleerekoper, M.; Lewiecki, E.M.; Miller, P.D.; Narula, H.S.; Pessah-Pollack, R.; Tangpricha, V.; Wimalawansa, S.J.; Watts, N.B. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016--Executive Summary. Endocr. Pract., 2016, 22(9), 1111-1118. doi: 10.4158/EP161435.ESGL PMID: 27643923
  57. Tu, K.N.; Lie, J.D.; Wan, C.K.V.; Cameron, M.; Austel, A.G.; Nguyen, J.K.; Van, K.; Hyun, D. Osteoporosis: A review of treatment options. P T, 2018, 43(2), 92-104. PMID: 29386866
  58. Lewiecki, E.M. Bisphosphonates for the treatment of osteoporosis: Insights for clinicians. Ther. Adv. Chronic Dis., 2010, 1(3), 115-128. doi: 10.1177/2040622310374783 PMID: 23251734
  59. Watts, N.B.; Diab, D.L. Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab., 2010, 95(4), 1555-1565. doi: 10.1210/jc.2009-1947 PMID: 20173017
  60. Fleisch, H. Bisphosphonates in osteoporosis. S. Afr. Pharm. J., 2017, 12, 60-64. doi: 10.1007/3-540-27376-X_8
  61. Caires, E.L.P.; Bezerra, M.C.; Junqueira, A.F.T de A.; Fontenele, S.M de A.; Andrade, S.C de A.; d’Alva, C.B. Treatment of postmenopausal osteoporosis: A literature-based algorithm for use in the public health care system. In: Rev. Bras. Reumatol. Engl. Ed; , 2017; 57, pp. (3)254-263. doi: 10.1016/j.rbre.2017.01.001
  62. Bone, H.G.; Hosking, D.; Devogelaer, J.P.; Tucci, J.R.; Emkey, R.D.; Tonino, R.P.; Rodriguez-Portales, J.A.; Downs, R.W.; Gupta, J.; Santora, A.C.; Liberman, U.A. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med., 2004, 350(12), 1189-1199. doi: 10.1056/NEJMoa030897 PMID: 15028823
  63. Compston, J. Practical guidance for the use of bisphosphonates in osteoporosis. Bone, 2020, 136, 115330. doi: 10.1016/j.bone.2020.115330 PMID: 32222607
  64. Chesnut, C.H., III; Skag, A.; Christiansen, C.; Recker, R.; Stakkestad, J.A.; Hoiseth, A.; Felsenberg, D.; Huss, H.; Gilbride, J.; Schimmer, R.C.; Delmas, P.D. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res., 2004, 19(8), 1241-1249. doi: 10.1359/JBMR.040325 PMID: 15231010
  65. Delmas, P.D.; Adami, S.; Strugala, C.; Stakkestad, J.A.; Reginster, J.Y.; Felsenberg, D.; Christiansen, C.; Civitelli, R.; Drezner, M.K.; Recker, R.R.; Bolognese, M.; Hughes, C.; Masanauskaite, D.; Ward, P.; Sambrook, P.; Reid, D.M. Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis Rheum., 2006, 54(6), 1838-1846. doi: 10.1002/art.21918 PMID: 16729277
  66. Ringe, J.D.; Dorst, A.; Faber, H.; Ibach, K.; Sorenson, F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: Results from a long-term comparative study. Osteoporos. Int., 2003, 14(10), 801-807. doi: 10.1007/s00198-003-1425-0 PMID: 14610641
  67. Black, D.M.; Rosen, C.J. Postmenopausal osteoporosis. N. Engl. J. Med., 2016, 374(3), 254-262. doi: 10.1056/NEJMcp1513724 PMID: 26789873
  68. Grey, A.; Bolland, M.; Wattie, D.; Horne, A.; Gamble, G.; Reid, I.R. Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. J. Bone Miner. Res., 2010, 25(10), 2251-2255. doi: 10.1002/jbmr.103 PMID: 20499349
  69. Kennel, K.A.; Drake, M.T. Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clin. Proc., 2009, 84(7), 632-638. doi: 10.1016/S0025-6196(11)60752-0
  70. Kanis, J.A.; Cooper, C.; Rizzoli, R.; Reginster, J.Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int., 2019, 30(1), 3-44. doi: 10.1007/s00198-018-4704-5 PMID: 30324412
  71. Khosla, S.; Burr, D.; Cauley, J.; Dempster, D.W.; Ebeling, P.R.; Felsenberg, D.; Gagel, R.F.; Gilsanz, V.; Guise, T.; Koka, S.; McCauley, L.K.; McGowan, J.; McKee, M.D.; Mohla, S.; Pendrys, D.G.; Raisz, L.G.; Ruggiero, S.L.; Shafer, D.M.; Shum, L.; Silverman, S.L.; Van Poznak, C.H.; Watts, N.; Woo, S.B.; Shane, E. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the american society for bone and mineral research. J. Bone Miner. Res., 2007, 22(10), 1479-1491. doi: 10.1359/jbmr.0707onj PMID: 17663640
  72. Cummings, S.R.; Schwartz, A.V.; Black, D.M. Alendronate and atrial fibrillation. N. Engl. J. Med., 2007, 356(18), 1895-1896. doi: 10.1056/NEJMc076132 PMID: 17476024
  73. Simm, P.J.; Biggin, A.; Zacharin, M.R.; Rodda, C.P.; Tham, E.; Siafarikas, A.; Jefferies, C.; Hofman, P.L.; Jensen, D.E.; Woodhead, H.; Brown, J.; Wheeler, B.J.; Brookes, D.; Lafferty, A.; Munns, C.F. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J. Paediatr. Child Health, 2018, 54(3), 223-233. doi: 10.1111/jpc.13768 PMID: 29504223
  74. Adler, R.A.; El-Hajj Fuleihan, G.; Bauer, D.C.; Camacho, P.M.; Clarke, B.L.; Clines, G.A.; Compston, J.E.; Drake, M.T.; Edwards, B.J.; Favus, M.J.; Greenspan, S.L.; McKinney, R., Jr; Pignolo, R.J.; Sellmeyer, D.E. Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the american society for bone and mineral research. J. Bone Miner. Res., 2016, 31(1), 16-35. doi: 10.1002/jbmr.2708 PMID: 26350171
  75. Milat, F.; Ebeling, P.R. Osteoporosis treatment: A missed opportunity. Med. J. Aust., 2016, 205(4), 185-190. doi: 10.5694/mja16.00568 PMID: 27510350
  76. David, P.S.; Sobel, T.; Sahni, S.; Mehta, J.; Kling, J.M. Menopausal hormone therapy in older women: Examining the current balance of evidence. Drugs Aging, 2023, 40(8), 675-683. doi: 10.1007/s40266-023-01043-3 PMID: 37344689
  77. Shah, N.; Ariel, D. The role of menopausal hormone therapy in the prevention and treatment of low bone density in perimenopausal and postmenopausal women. Curr. Opin. Obstet. Gynecol., 2023, 35(2), 141-149. doi: 10.1097/GCO.0000000000000858 PMID: 36912327
  78. Vinogradova, Y.; Coupland, C.; Hippisley-Cox, J. Use of hormone replacement therapy and risk of breast cancer: Nested case-control studies using the QResearch and CPRD databases. BMJ, 2020, 371, m3873. doi: 10.1136/bmj.m3873 PMID: 33115755
  79. Mehta, J.; Kling, J.M.; Manson, J.E. Risks, benefits, and treatment modalities of menopausal hormone therapy: Current concepts. Front. Endocrinol., 2021, 12, 564781. doi: 10.3389/fendo.2021.564781 PMID: 33841322
  80. Muñoz-Torres, M.; Alonso, G.; Raya, M.P. Calcitonin therapy in osteoporosis. Treat. Endocrinol., 2004, 3(2), 117-132. doi: 10.2165/00024677-200403020-00006 PMID: 15743107
  81. Peña-Rodríguez, Z.A.; Haro-García, M.; Benito-Navarro, J.R. Nasal osteoma and inhaled salmon calcitonin: Coincidence or consequence? Acta Otorrinolaringologica, 2017, 68(6), 366-368. doi: 10.1016/j.otoeng.2017.10.002 PMID: 28069111
  82. Nelson, E.R.; Wardell, S.E.; McDonnell, D.P. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis. Bone, 2013, 53(1), 42-50. doi: 10.1016/j.bone.2012.11.011 PMID: 23168292
  83. An, K.C. Selective estrogen receptor modulators. Asian Spine J., 2016, 10(4), 787-791. doi: 10.4184/asj.2016.10.4.787 PMID: 27559463
  84. Hadji, P. The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric, 2012, 15(6), 513-523. doi: 10.3109/13697137.2012.688079 PMID: 22853318
  85. Johnston, C.C., Jr; Bjarnason, N.H.; Cohen, F.J.; Shah, A.; Lindsay, R.; Mitlak, B.H.; Huster, W.; Draper, M.W.; Harper, K.D.; Heath, H., III; Gennari, C.; Christiansen, C.; Arnaud, C.D.; Delmas, P.D. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch. Intern. Med., 2000, 160(22), 3444-3450. doi: 10.1001/archinte.160.22.3444 PMID: 11112238
  86. Gennari, L.; Merlotti, D.; Nuti, R. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: Focus on lasofoxifene. Clin. Interv. Aging, 2010, 5, 19-29. doi: 10.2147/CIA.S6083 PMID: 20169039
  87. Gennari, L.; Merlotti, D.; De Paola, V.; Martini, G.; Nuti, R. Bazedoxifene for the prevention of postmenopausal osteoporosis. Ther. Clin. Risk Manag., 2008, 4(6), 1229-1242. doi: 10.2147/TCRM.S3476 PMID: 19337430
  88. Orwoll, E.S.; Bilezikian, J.P.; Vanderschueren, D. Osteoporosis in Men; Elsevier, 2010. doi: 10.1016/C2009-0-02210-7
  89. Zaheer, S.; LeBoff, M.; Lewiecki, E.M. Denosumab for the treatment of osteoporosis. Expert Opin. Drug Metab. Toxicol., 2015, 11(3), 461-470. doi: 10.1517/17425255.2015.1000860 PMID: 25614274
  90. Cummings, SR; Martin, JS; McClung, MR; Siris, ES; Eastell, R; Reid, IR Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med., 2009, 361(8), 756-765. doi: 10.1056/NEJMoa0809493
  91. Zhang, N.; Zhang, Z.K.; Yu, Y.; Zhuo, Z.; Zhang, G.; Zhang, B.T. Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy. Front. Cell Dev. Biol., 2020, 8, 325. doi: 10.3389/fcell.2020.00325 PMID: 32478071
  92. Lane, N.E.; Kelman, A. A review of anabolic therapies for osteoporosis. Arthritis Res., 2003, 5(5), 214-222. doi: 10.1186/ar797 PMID: 12932280
  93. Martin, T.J. Bone biology and anabolic therapies for bone: Current status and future prospects. J. Bone Metab., 2014, 21(1), 8-20. doi: 10.11005/jbm.2014.21.1.8 PMID: 24707463
  94. Wojda, S.J.; Donahue, S.W. Parathyroid hormone for bone regeneration. J. Orthop. Res., 2018, 36(10), 2586-2594. doi: 10.1002/jor.24075 PMID: 29926970
  95. Riggs; Redman, C.; Riggs, A. Teriparatide in the management of osteoporosis. Clin. Interv. Aging, 2008, 2(4), 499-507. doi: 10.2147/CIA.S241 PMID: 18225450
  96. Langdahl, B.L.; Silverman, S.; Fujiwara, S.; Saag, K.; Napoli, N.; Soen, S.; Enomoto, H.; Melby, T.E.; Disch, D.P.; Marin, F.; Krege, J.H. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone, 2018, 116, 58-66. doi: 10.1016/j.bone.2018.07.013 PMID: 30021126
  97. Miller, P.D.; Hattersley, G.; Lau, E.; Fitzpatrick, L.A.; Harris, A.G.; Williams, G.C.; Hu, M.Y.; Riis, B.J.; Russo, L.; Christiansen, C. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. Bone, 2019, 120, 137-140. doi: 10.1016/j.bone.2018.10.015 PMID: 30359763
  98. Chandler, H.; Lanske, B.; Varela, A.; Guillot, M.; Boyer, M.; Brown, J.; Pierce, A.; Ominsky, M.; Mitlak, B.; Baron, R.; Kostenuik, P.; Hattersley, G. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone, 2019, 120, 148-155. doi: 10.1016/j.bone.2018.10.012 PMID: 30343166
  99. Leder, B.Z.; Tsai, J.N.; Uihlein, A.V.; Burnett-Bowie, S.A.M.; Zhu, Y.; Foley, K.; Lee, H.; Neer, R.M. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): A randomized controlled trial. J. Clin. Endocrinol. Metab., 2014, 99(5), 1694-1700. doi: 10.1210/jc.2013-4440 PMID: 24517156
  100. Girotra, M.; Rubin, M.R.; Bilezikian, J.P. Anabolic skeletal therapy for osteoporosis. Arq. Bras. Endocrinol. Metabol, 2006, 50(4), 745-754. doi: 10.1590/S0004-27302006000400019 PMID: 17117299
  101. Blake, G.M.; Fogelman, I. Strontium ranelate: A novel treatment for postmenopausal osteoporosis: A review of safety and efficacy. Clin. Interv. Aging, 2006, 1(4), 367-375. doi: 10.2147/ciia.2006.1.4.367 PMID: 18046914
  102. McGreevy, C.; Williams, D. Safety of drugs used in the treatment of osteoporosis. Ther. Adv. Drug Saf., 2011, 2(4), 159-172. doi: 10.1177/2042098611411012 PMID: 25083210
  103. Cianferotti, L.; D’Asta, F.; Brandi, M.L. A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther. Adv. Musculoskelet. Dis., 2013, 5(3), 127-139. doi: 10.1177/1759720X13483187 PMID: 23858336
  104. Kaufman, J.M.; Audran, M.; Bianchi, G.; Braga, V.; Diaz-Curiel, M.; Francis, R.M.; Goemaere, S.; Josse, R.; Palacios, S.; Ringe, J.D.; Felsenberg, D.; Boonen, S. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J. Clin. Endocrinol. Metab., 2013, 98(2), 592-601. doi: 10.1210/jc.2012-3048 PMID: 23341486
  105. Lim, S.Y.; Bolster, M. Profile of romosozumab and its potential in the management of osteoporosis. Drug Des. Devel. Ther., 2017, 11, 1221-1231. doi: 10.2147/DDDT.S127568 PMID: 28458516
  106. McClung, M.R.; Grauer, A.; Boonen, S.; Bolognese, M.A.; Brown, J.P.; Diez-Perez, A.; Langdahl, B.L.; Reginster, J-Y.; Zanchetta, J.R.; Wasserman, S.M.; Katz, L.; Maddox, J.; Yang, Y-C.; Libanati, C.; Bone, H.G. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med., 2014, 370(5), 412-420. doi: 10.1056/NEJMoa1305224
  107. Langdahl, B.L.; Libanati, C.; Crittenden, D.B.; Bolognese, M.A.; Brown, J.P.; Daizadeh, N.S.; Dokoupilova, E.; Engelke, K.; Finkelstein, J.S.; Genant, H.K.; Goemaere, S.; Hyldstrup, L.; Jodar-Gimeno, E.; Keaveny, T.M.; Kendler, D.; Lakatos, P.; Maddox, J.; Malouf, J.; Massari, F.E.; Molina, J.F.; Ulla, M.R.; Grauer, A. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial. Lancet, 2017, 390(10102), 1585-1594. doi: 10.1016/S0140-6736(17)31613-6 PMID: 28755782
  108. Ferrari, SL Romosozumab to rebuild the foundations of bone strength. Nat. Rev. Rheumatol., 2018, 14, 128. doi: 10.1038/nrrheum.2018.5
  109. Kaveh, S.; Hosseinifard, H.; Ghadimi, N.; Vojdanian, M.; Aryankhesal, A. Efficacy and safety of Romosozumab in treatment for low bone mineral density: A systematic review and meta-analysis. Clin. Rheumatol., 2020, 39(11), 3261-3276. doi: 10.1007/s10067-020-04948-1 PMID: 32385757
  110. Zhang, C.; Song, C. Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives. Front. Pharmacol., 2021, 11, 607017. doi: 10.3389/fphar.2020.607017 PMID: 33584284
  111. Lou, S.; Lv, H.; Li, Z.; Zhang, L.; Tang, P. Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: A meta-analysis of randomised controlled trials. BMJ Open, 2018, 8(3), e015187. doi: 10.1136/bmjopen-2016-015187 PMID: 29500198
  112. Tsai, J.N.; Uihlein, A.V.; Burnett-Bowie, S.M.; Neer, R.M.; Derrico, N.P.; Lee, H.; Bouxsein, M.L.; Leder, B.Z. Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study). J. Clin. Endocrinol. Metab., 2016, 101(5), 2023-2030. doi: 10.1210/jc.2016-1160 PMID: 26964731
  113. Ramchand, S.K.; David, N.L.; Lee, H.; Bruce, M.; Bouxsein, M.L.; Leder, B.Z.; Tsai, J.N. Effects of combination denosumab and HIGH-DOSE teriparatide administration on bone microarchitecture and estimated strength: The DATA-HD HR-PQCT study. J. Bone Miner. Res., 2021, 36(1), 41-51. doi: 10.1002/jbmr.4161 PMID: 32790196
  114. Nakamura, Y.; Suzuki, T.; Kamimura, M.; Ikegami, S.; Murakami, K.; Uchiyama, S.; Taguchi, A.; Kato, H. Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women. Bone Res., 2017, 5(1), 16055. doi: 10.1038/boneres.2016.55 PMID: 28690911
  115. Finkelstein, J.S.; Wyland, J.J.; Lee, H.; Neer, R.M. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab., 2010, 95(4), 1838-1845. doi: 10.1210/jc.2009-1703 PMID: 20164296
  116. Li, Y.F.; Zhou, C.C.; Li, J.H.; Luo, E.; Zhu, S.S.; Feng, G.; Hu, J. The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos. Int., 2012, 23(4), 1463-1474. doi: 10.1007/s00198-011-1751-6 PMID: 21892678
  117. Roux, S. New treatment targets in osteoporosis. Joint Bone Spine, 2010, 77(3), 222-228. doi: 10.1016/j.jbspin.2010.02.004 PMID: 20381400
  118. Iñiguez-Ariza, N.M.; Clarke, B.L. Bone biology, signaling pathways, and therapeutic targets for osteoporosis. Maturitas, 2015, 82(2), 245-255. doi: 10.1016/j.maturitas.2015.07.003 PMID: 26255682
  119. Dai, R.; Wu, Z.; Chu, H.Y.; Lu, J.; Lyu, A.; Liu, J.; Zhang, G.; Cathepsin, K. The action in and beyond bone. Front. Cell Dev. Biol., 2020, 8, 433. doi: 10.3389/fcell.2020.00433 PMID: 32582709
  120. Muniyasamy, R.; Manjubala, I. Identification of potential sclerostin inhibiting flavonoids from Oroxylum indicum: An in silico approach. J. Biomol. Struct. Dyn., 2023, 1-12. doi: 10.1080/07391102.2023.2239955 PMID: 37493468
  121. Adhish, M.; Manjubala, I. An in-silico approach to the potential modulatory effect of taurine on sclerostin (SOST) and its probable role during osteoporosis. J. Biomol. Struct. Dyn., 2023, 0, 1-16. doi: 10.1080/07391102.2023.2249103 PMID: 37608541
  122. Jiang, H.; Zhang, Z.; Yu, Y.; Chu, H.Y.; Yu, S.; Yao, S.; Zhang, G.; Zhang, B.T. Drug discovery of DKK1 inhibitors. Front. Pharmacol., 2022, 13, 847387. doi: 10.3389/fphar.2022.847387 PMID: 35355709
  123. Jiang, Y.; Zhang, P.; Zhang, X.; Lv, L.; Zhou, Y. Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis. Cell Prolif., 2021, 54(1), e12956. doi: 10.1111/cpr.12956 PMID: 33210341
  124. Rudiansyah, M.; El-Sehrawy, A.A.; Ahmad, I.; Terefe, E.M.; Abdelbasset, W.K.; Bokov, D.O.; Salazar, A.; Rizaev, J.A.; Muthanna, F.M.S.; Shalaby, M.N. Osteoporosis treatment by mesenchymal stromal/stem cells and their exosomes: Emphasis on signaling pathways and mechanisms. Life Sci., 2022, 306, 120717. doi: 10.1016/j.lfs.2022.120717 PMID: 35792178
  125. Tang, G.; Liu, Z.; Liu, Y.; Yu, J.; Wang, X.; Tan, Z.; Ye, X. Recent trends in the development of bone regenerative biomaterials. Front. Cell Dev. Biol., 2021, 9, 665813. doi: 10.3389/fcell.2021.665813 PMID: 34026758
  126. Arcos, D.; Boccaccini, A.R.; Bohner, M.; Díez-Pérez, A.; Epple, M.; Gómez-Barrena, E.; Herrera, A.; Planell, J.A.; Rodríguez-Mañas, L.; Vallet-Regí, M. The relevance of biomaterials to the prevention and treatment of osteoporosis. Acta Biomater., 2014, 10(5), 1793-1805. doi: 10.1016/j.actbio.2014.01.004 PMID: 24418434
  127. Arkin, V.H.; Narendrakumar, U.; Madhyastha, H.; Manjubala, I. Characterization and in vitro evaluations of injectable calcium phosphate cement doped with magnesium and strontium. ACS Omega, 2021, 6(4), 2477-2486. doi: 10.1021/acsomega.0c03927 PMID: 33553866
  128. v K, A.D.; Ray, S.; Arora, U.; Mitra, S.; Sionkowska, A.; Jaiswal, A.K. Dual drug delivery platforms for bone tissue engineering. Front. Bioeng. Biotechnol., 2022, 10, 969843. doi: 10.3389/fbioe.2022.969843 PMID: 36172012
  129. Ding, K.; Hua, F.; Ding, W. Gut microbiome and osteoporosis. Aging Dis., 2020, 11(2), 438-447. doi: 10.14336/AD.2019.0523 PMID: 32257552
  130. Black, D.M.; Cummings, S.R.; Karpf, D.B.; Cauley, J.A.; Thompson, D.E.; Nevitt, M.C.; Bauer, D.C.; Genant, H.K.; Haskell, W.L.; Marcus, R.; Ott, S.M.; Torner, J.C.; Quandt, S.A.; Reiss, T.F.; Ensrud, K.E. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet, 1996, 348(9041), 1535-1541. doi: 10.1016/S0140-6736(96)07088-2 PMID: 8950879
  131. McClung, M.R.; Geusens, P.; Miller, P.D.; Zippel, H.; Bensen, W.G.; Roux, C.; Adami, S.; Fogelman, I.; Diamond, T.; Eastell, R.; Meunier, P.J.; Wasnich, R.D.; Greenwald, M.; Kaufman, J-M.; Chesnut, C.H.; Reginster, J-Y. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med., 2001, 344(5), 333-340. doi: 10.1056/NEJM200102013440503 PMID: 11172164
  132. Black, D.M.; Delmas, P.D.; Eastell, R.; Reid, I.R.; Boonen, S.; Cauley, J.A.; Cosman, F.; Lakatos, P.; Leung, P.C.; Man, Z.; Mautalen, C.; Mesenbrink, P.; Hu, H.; Caminis, J.; Tong, K.; Rosario-Jansen, T.; Krasnow, J.; Hue, T.F.; Sellmeyer, D.; Eriksen, E.F.; Cummings, S.R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med., 2007, 356(18), 1809-1822. doi: 10.1056/NEJMoa067312 PMID: 17476007

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers